vimarsana.com

Page 4 - ஆர்க்டரஸ் சிகிச்சை ஹோல்டிங்ஸ் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

American Realty Capital Trust, Inc (NASDAQ:ARCT) - Arcturus Therapeutics: Q1 Earnings Insights

52-week low: $28.92 Company Description Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-2020.   Related Articles (ARCT)

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

The mRNA IP and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II) | Rothwell, Figg, Ernst & Manbeck, P C

To embed, copy and paste the code into your website or blog: In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac. In this second post, we will focus on Translate BIO, Arcturus Therapeutics, and eTheRNA and discuss certain issues relating to lipid nanoparticle (LNP) delivery technology. More mRNA Market Players Translate Bio Translate Bio, Inc. (NASDAQ: TBIO) is headquartered in Lexington, MA, and as of April 2021, has a market capitalization of over $1.3 billion. According to its website, Translate BIO’s mRNA product pipeline is directed to several indications including cystic fibrosis, primary ciliary dyskinesia, pulmonary arterial hypertension, COVID-19, influenza, viral pathogens, and bacterial pathogens.

The Pandemic Year s Top Stock-Fund Managers — Journal Report

Provided by Dow Jones By Suzanne McGee In late March of last year, as the world started to deal with the pandemic lockdowns, the U.S. stock market had already hit reset. A year later, as investors closed the books for the first quarter of 2021, they are looking back on a market rebound that outdid even the post-financial-crisis recovery for both speed and magnitude. How did the professional stock pickers at mutual funds do? Overall, no better than an index fund. But the best of them blew away the field including a spectacular 273% gain for the No. 1 fund, the small-stock-focused Morgan Stanley Inception Portfolio (MSSGX).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.